Quick Links
University of California,
San Diego (UCSD)
Rebecca and John Moores UCSD
Cancer Center
La Jolla, CA
The Burnham Institute
La Jolla, CA
Dana Farber Cancer Institute
Harvard Medical School
Boston, MA
Johns Hopkins University
Oncology Center
Baltimore, MD
Long Island Jewish Medical
Center
Division of Hematology/Oncology
New Hyde Park, NY
M.D. Anderson Cancer Center
Houston, TX
Ohio State University
Cancer Center
Columbus, Ohio
Barts Cancer Centre of
Excellence
Barts Hospital
West Smithfield, London
Mayo Clinic
Rochester, MN
Heavy Water
Protocol
Participating Sites
M.D. Anderson Cancer Center
Houston, TX
University of California,
San Diego (UCSD)
Rebecca and John Moores
UCSD Cancer Center
La Jolla, CA
Dana Farber
Cancer Institute
Harvard Medical School
Boston, MA
Ohio State University
Cancer Center
Columbus, Ohio
Mayo Clinic
Rochester, MN
Long Island Jewish
Medical
Center
Division of Hematology/Oncology
New Hyde Park, NY
Please contact the participating site to setup an appointment or to get more informaiton.
CRC 011: Kinetic Biomarker for Chronic Lymphocytic Leukemia (CLL)
Prognosis
PHASE II: 1) Establish the sensitivity and specificity of the KineMarker™
measurement of in vivo B-CLL kinetics as a test for predicting subsequent
clinical course in 150 B-CLL patients, through a 2-4 year prospective
study; 2)Compare the KineMarker™ test in B-CLL patients to other
established and candidate prognostic tests.